Bristol Sprycel Receives Broad Committee Support For Leukemia Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee votes unanimously in favor of dasatinib approval for all phases of Gleevec-resistant or intolerant CML.
You may also be interested in...
Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML
Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.
Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML
Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.
Bristol’s Sprycel To Launch “Within Days”
FDA grants dasatinib accelerated approval for all phases of chronic myeloid leukemia in patients resistant to or intolerant of Novartis’ Gleevec.